Home
NewsNewsRenew Biotech confirms being a clinical testing provider for NOA Guide by Path Fertility, offering advanced evaluation for men with non-obstructive azoospermia, a form of male infertility.
Renew Biotechnologies, on January 29, 2025, went on to announce as Renew becomes clinical testing provider for NOA Guide by Path Fertility, which apparently is a newly launched epigenetic diagnostic test that is designed to inform surgical decision-making when it comes to men having non-obstructive azoospermia – NOA, which is a form of male infertility.
It is worth noting that the NOA Guide makes utmost use of the native-read sequencing technology by Renew so as to directly measure the epigenetic signals sans any sort of amplification or even chemical conversion and is enhanced so as to detect the quantifying sperm-derived cell-free DNA - cfDNA from the seminal samples.
The test is going to be processed by Wasatch BioLabs, which is a subsidiary of Renew and acts as the centralized core lab across all research and clinical sample processing. The test indeed addresses a long-standing gap when it comes to male infertility care. Patients having azoospermia most often than not go through surgical sperm retrieval, having limited ability to forecast if sperm are present or retrievable. Through identifying cfDNA signatures, which are associated with spermatogenesis, even at the time when the intact sperm are not observed, NOA Guide provides a minimally invasive way to evaluate the underlying production and also retrieval potential.
The collaboration has in it assay development and validation along with clinical-grade processing, helping with dependable epigenetic measurement, which is suitable for routine clinical usage with downstream effects when it comes to reproductive decision-making. According to co-founder & CEO Chad Pollard of Renew Biotechnologies, which is going to be the clinical testing provider for NOA Guide by Path Fertility, "Programs like NOA Guide reflect the type of diagnostic innovation we are focused on enabling. Our role is to help transform emerging biological insights into analytically sound, clinically operational tests through rigorous development and clinical processing."
Kristin Brogaard, PhD, Co-founder & CSO, Path Fertility, opines that "For men with non-obstructive azoospermia, the decision to pursue surgical sperm retrieval can be daunting and deeply personal. NOA Guide brings epigenetic insight earlier in the care journey, helping patients and clinicians approach these decisions with greater clarity and confidence."
Interestingly, the scientific foundation for the NOA Guide was created in partnership with academic researchers Dr. Tim Jenkins, Dr. Jonathon Hill, and Ryan Miller, as well as Dr. Ryan Barney, all from Brigham Young University, alongside major contributions coming in from the Path Fertility team’s Dr. Kristin Brogaard and Derek Petersen.
Through supporting diagnostic innovators such as Path Fertility, Renew Biotechnologies advances novel clinical applications that have come into existence through native-read sequencing, as Renew Becomes Clinical Testing–ready in its approach, enabling the partners to translate the biological insights that are emerging into analytically strong and clinically deployable diagnostics.
Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.
From 1 July 2026, South Australia's Fertility Treatment Rebate Scheme provides eligible residents with a $250 rebate for pre-treatment testing and a $2,000 rebate for up to two fertility treatment cycles. Backed by an $18.5 million, four-year government commitment, the scheme directly addresses the financial barriers preventing South Australians from accessing fertility care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
